BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gavini MP, Mahmood A, Belenchia AM, Beauparlant P, Kumar SA, Ardhanari S, DeMarco VG, Pulakat L. Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4. Front Pharmacol 2021;12:693167. [PMID: 34220518 DOI: 10.3389/fphar.2021.693167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Ameer OZ. Hypertension in chronic kidney disease: What lies behind the scene. Front Pharmacol 2022;13:949260. [DOI: 10.3389/fphar.2022.949260] [Reference Citation Analysis]
2 Steckelings UM, Widdop RE, Sturrock ED, Lubbe L, Hussain T, Kaschina E, Unger T, Hallberg A, Carey RM, Sumners C. The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target. Pharmacol Rev 2022;74:1051-135. [PMID: 36180112 DOI: 10.1124/pharmrev.120.000281] [Reference Citation Analysis]
3 Papadopoulos KI, Sutheesophon W, Aw TC. The influence of renin angiotensin aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS) and erythropoietin (EPO) on COVID-19 complications. Chem Biol Interact 2022;354:109834. [PMID: 35092718 DOI: 10.1016/j.cbi.2022.109834] [Reference Citation Analysis]
4 Speth RC. Renin-Angiotensin-Aldosterone System. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00160-2] [Reference Citation Analysis]
5 Papadopoulos KI, Sutheesophon W, Manipalviratn S, Aw TC. Age and genotype dependent erythropoietin protection in COVID-19. World J Stem Cells 2021;13:1513-29. [PMID: 34786155 DOI: 10.4252/wjsc.v13.i10.1513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]